Phenotypic and genotypic risk factors for cardiovascular events in an incident dialysis cohort

Kidney International

Volumn 69, Issue 8, 2006, Pages 1424-1430

  Pernod, G ^a   Bosson, J L ^a   Golshayan, D ^b   Barro, C ^a   Forneris, G ^c   Martina, G ^d   Bonfant, G ^e   Hurot, J M ^f   Turc Baron, C ^g   Jouet, C ^h   Theytaz, J ^b   Jeantet, A ^d   Wauters, J P ^b,i   Cordonnier, D ^h  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c S GIOVANNI BOSCO HOSPITAL   (Italy)

^d MOLINETTE HOSPITAL   (Italy)

^e Aosta Hospital   (Italy)

^f Tassin Center for Dialysis   (France)

^g Centre Hospitalier de la Region d'Annecy   (France)

^h AGDUC   (France)

ⁱ Klinik fur Nephrologie Hypertonie   (Switzerland)

Author keywords

Cardiovascular risk; Dialysis; Homocysteine; Lp(a); Mortality study; MTHFR

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE; LIPOPROTEIN A;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COHORT ANALYSIS; FEMALE; GENOTYPE; HEMODIALYSIS; HIGH RISK PATIENT; HOMOCYSTINURIA; HUMAN; KIDNEY FAILURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; FRANCE; GENOTYPE; HUMANS; INCIDENCE; ITALY; MALE; MIDDLE AGED; MORBIDITY; MULTIVARIATE ANALYSIS; PHENOTYPE; PREVALENCE; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS; SWITZERLAND; TIME FACTORS; TREATMENT OUTCOME;

EID: 33646158696     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000312     Document Type: Article

References (39)

1. Locatelli F, Marcelli D, Conte F et al. Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease. J Am Soc Nephrol 2001; 12: 2411-2417.
2. Cheung AK, Sarnak MJ, Yan G et al. Atherosclerotic cardio-vascular disease risks in chronic hemodialysis patients. Kidney Int 2000; 58: 353-362.
3. Guérin A, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-1021.
4. Foley RN, Parfrey PS, Harnett JD et al. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996; 49: 1379-1385.
5. Cheng SW, Ting AC, Wong J. Fasting total plasma homocysteine and atherosclerotic peripheral vascular disease. Ann Vasc Surg 1997; 11: 217-223.
6. Cheng SW, Ting AC, Wong J. Lipoprotein (a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease, Eur J Vasc Endovasc Surg 1997; 14: 17-23.
7. Maggi E, Bellazzi R, Gazo A et al. Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney Int 1994; 46: 869-876.
8. Olmer M, Renucci JE, Planells R et al. Preliminary evidence for a role of apolipoprotein E alleles in identifying haemodialysis patients at high vascular risk. Nephrol Dial Transplant 1997; 12: 691-693.
9. Kronenberg F, Neyer U, Lhotta K et al. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol 1999; 10: 1027-1036.
10. Kimura H, Gejyo F, Suzuki S et al. A C677T mutation in the 5, 10-methylenetetrahydrofolate reductase gene modifies serum cysteine in dialysis patients. Am J Kidney Dis 2000; 36: 925-933.
11. Cambien F, Poirier O, Lecerf L et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359: 641-644.
12. Wong TY, Poon P, Szeto CC et al. Association of plasminogen activator inhibitor-1 4G/4G genotype and type 2 diabetic nephropathy in Chinese patients. Kidney Int 2000; 57: 632-638.
13. Pernod G, Bosson JL, Golshayan D et al. The Diamant Alpin Dialysis cohort study: clinico-biological characteristics and cardiovascular genetic risk profile of incident patients. J Nephrol 2004; 17: 66-75.
14. Wauters JP, Bosson JL, Forneris G et al. Patients referral is influenced by dialysis center structure in the Diamant Alpin Dialysis cohort study. Nephrol Dial Transplant 2004; 19: 2341-2346.
15. US Renal Data System. USRDS 1998 Annual Data Report, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease: Bethesda, MD; April 1998.
16. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998; 339: 799-805.
17. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999; 10: 1606-1615.
18. Levin A. Clinical epidemiology of cardio-vascular disease in chronic kidney disease prior to dialysis. Semin Dialysis 2003; 16: 101-105.
19. Ritz E, Mc Clellan WM. Increased cardio-vascular risk in patients with minor renal dysfunction: an emerging issue with far reaching consequences. J Am Soc Nephrol 2004; 115: 513-516.
20. Zoccali C, Mallamaci F, Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int 2003; 63: S105-S110.
21. Kalantar-Zadeh K, Block G, Humphreys MH et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793-808.
22. Blacher J, Guerin AP, Pannier B et al. Arterial calcifications, arterial stiffness, and cardio-vascular risk in end-stage renal disease. Hypertension 2001; 38: 938-942.
23. Stenvinkel P, Heimburger O, Paultre F et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-1911.
24. Joki N, Hase H, Takahashi Y et al. Angiographical severity of coronary atherosclerosis predicts death in the first year of hemodialysis. Int Urol Nephrol 2003; 35: 289-297.
25. Wheeler DC, Townend JN, Landray MJ. Cardiovascular risk factors in predialysis patients: baseline data from the Chronic Renal Impairment in Birmingham (CRIB) study. Kidney Int Suppl 2003; 63: S201-S203.
26. Alan S, Go AS, Chertow GM et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
27. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102: 1082-1085.
28. Longenecker JC, Coresh J, Marcovina SM et al. Lipoprotein(a) and prevalent cardiovascular disease in a dialysis population: The Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study. Am J Kidney Dis 2003; 42: 108-116.
29. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of total plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-1057.
30. Chauveau P, Chadefaux B, Coude M et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 1993; 41: S72-S77.
31. Bostom AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997; 52: 10-20.
32. Moustapha A, Naso A, Nahlawi M et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998; 97: 138-141.
33. Mallamaci F, Zoccali C, Tripepi G et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 2002; 61: 609-614.
34. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease: a common mutation in 5, 10-methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113.
35. Wrone EM, Zehnder JL, Hornberger JM et al. An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease. Kidney Int 2001; 60: 1106-1113.
36. Clarke R, Lewington S, Landray M. Homocysteine, renal function, and risk of cardiovascular disease. Kidney Int 2003; 63: S131-S133.
37. Fukasawa M, Matsushita K, Kamiyama M et al. The methylenetetrahydrofolate reductase C677T point mutation is a risk factor for vascular access thrombosis in hemodialysis patients. Am J Kidney Dis 2003; 41: 637-642.
38. Nakamura T, Saionji K, Hiejima Y et al. Methylenetetrahydrofolate reductase genotype, vitamin B12, and folate influence total plasma homocysteine in hemodialysis patients. Am J Kidney Dis 2002; 39: 1032-1039.
39. Ducros V, Schmitt D, Pernod G et al. Gas chromatographic-mass spectrometric determination of total homocysteine in human plasma by stable isotope dilution: method and clinical applications. J Chromatogr B 1999; 729: 333-339.